The buyout also bolstered biotechnology sector-related ETFs with a small-cap tilt. For instance, the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) focuses on small- and mid-cap companies that have one or more drugs in either Phase II or Phase III U.S. FDA clinical trials. The broader SPDR S&P Biotech ETF (NYSEArca: XBI) follows an equal-weight index of biotechnology companies, with 23.9% in micro-caps, 35.7% small-caps and 22.2% mid-caps. ANAC makes up 3.4% of SBIO and 2.0% of XBI.
On Monday, SBIO increased 4.7% and XBI rose 4.1%.
ALPS Medical Breakthroughs ETF (NYSEArca: SBIO)